Archive · 27 Oct 2025
Stempeutics, Medinet Partner for Stem Cell Therapy in Japan
Imagine a problem where blood flow to your legs is blocked, potentially leading to serious sores and even amputation.
Stempeutics, an Indian company, has a special treatment called Stempeucel using stem cells.
They've partnered with Medinet, a Japanese company, to bring this treatment to Japan.
This means Medinet will conduct further studies to get approval, using data from existing trials in India.
If all goes well, patients in Japan could benefit from this treatment in the future.
The product is made from stem cells from healthy donors, and helps restore blood flow, which is crucial for those suffering from this painful condition.
Stempeutics has signed an option license agreement with Medinet to bring its stem cell product to Japan.
The product, Stempeucel, is for treating Chronic Limb Threatening Ischemia (CLTI).
Medinet will conduct a pivotal study in Japan; Stempeutics will provide regulatory information.
Stempeutics will have to meet regulatory milestones before market entry.
The deal includes upfront payments, milestone payments, and royalties if the product reaches the market.
- Who
- Stempeutics and Medinet
- What
- Entered an agreement for Stempeucel, a stem cell product, to be used in Japan for CLTI.
- When
- Agreement formalized on an undisclosed date, after approximately two and a half years of discussion.
- Where
- Japan
- Why
- To introduce stem cell therapy for Chronic Limb Threatening Ischemia in Japan.
- Companies Involved
- Stempeutics (India), Medinet (Japan)
- Product
- Stempeucel (for CLTI)
- Deal Type
- Option License Agreement
- Treatment Target
- Chronic Limb Threatening Ischemia (CLTI)
- Stempeutics Stakeholder
- Cipla (34%)
- Patients Treated (India)
- 600+ with CLTI